Evaluation of the Efficacy of Early Bunching of a FF-PCC in Patients With Severe Traumatic Hemorrhage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
|ClinicalTrials.gov Identifier: NCT05738642
Recruitment Status : Not yet recruiting
First Posted : February 22, 2023
Last Update Posted : February 22, 2023
Uncontrolled hemorrhage within 24 hours after severe trauma is the main cause of death in trauma patients. Hemorrhagic shock may be accompanied by traumatic coagulopathy in the early stages of severe trauma. Among them, the main pathogenesis of traumatic coagulation disorder is tissue injury, hypoperfusion, inflammatory response and acute neurohumoral system activation leading to the activation of endogenous protein C, increased consumption of coagulation factor, loss of coagulation factor caused by massive bleeding, low temperature and other factors aggravate the disorder of coagulation function and cause hyperfibrinolysis. Studies have shown that the fatality rate of patients with severe traumatic coagulopathy is 4-8 times higher than that of patients without coagulopathy. Active and effective injury-controlled resuscitation and surgical treatment, target-oriented supplementation of coagulation substrate and correction of coagulation function are the main measures for high-quality treatment of patients with severe trauma. Therefore, early improvement of coagulation function is the key to improve the comprehensive treatment level of patients with severe trauma.
At present, four-factor prothrombin complex (4F-PCC) is a compound preparation containing coagulation factors Ⅱ, VII, IX and X separated from fresh plasma of healthy people. It is used in clinical treatment of patients with coagulation factor deficiency or bleeding complicated by taking anticoagulant drugs to achieve rapid hemostasis effect. However, large-scale, long-term observation of the efficacy and safety of the early application of cluster infusion of 4F-PCC in traumatic massive hemorrhage, correction of cocoagulation dysfunction, and improvement of clinical prognosis has not been proven.
This study intends to conduct a clinical intervention study on early bunching and sufficient use of 4F-PCC in patients with severe traumatic massive hemorrhage, and evaluate its efficacy in early use of severe traumatic massive hemorrhage through a randomized controlled and open-label clinical study of multi-center, bunching use of PCC in patients with severe traumatic massive hemorrhage.
|Condition or disease
|Drug: 4 factor Prothrombin Complex Concentrates
|Study Type :
|Interventional (Clinical Trial)
|Estimated Enrollment :
|None (Open Label)
|Evaluation of the Efficacy of Early Bunching of a Four-factor Prothrombin Complex Concentrates in Patients With Severe Traumatic Hemorrhage: a Multicenter, Randomized Controlled, Open-label Clinical Study
|Estimated Study Start Date :
|March 1, 2023
|Estimated Primary Completion Date :
|December 31, 2025
|Estimated Study Completion Date :
|December 31, 2025
Experimental: 4F-PCC group
1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function. 2. 4 F- PCC by intravenous infusion of cluster
Drug: 4 factor Prothrombin Complex Concentrates
Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
Other Name: test group
No Intervention: non 4F-PCC group
1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function.
- Incidence of multiple organ failure within 7 days [ Time Frame: 7 days ]
- mortality at 28 days [ Time Frame: 28 days ]
- The total transfusion volume of blood products within 24 hours after trauma [ Time Frame: 28 days ]The total transfusion volume of blood products within 24 hours after trauma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05738642
|Contact: yongan xu, doctor
|yongan xu, doctor
|Second Affiliated Hospital, School of Medicine, Zhejiang University